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In Brief
Boege et al. identify persistent
hepatocyte apoptosis as a determinant of
hepatocellular carcinoma development.
They show that caspase-8 not only
executes hepatocyte apoptosis but also
has a non-apoptotic role in proliferation-
associated DNA damage response
mediated by a caspase-8/RIPK1/FADD/
c-FLIP complex.
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SUMMARY
Concomitant hepatocyte apoptosis and regeneration is a hallmark of chronic liver diseases (CLDs) predis-
posing to hepatocellular carcinoma (HCC). Here, we mechanistically link caspase-8-dependent apoptosis
to HCC development via proliferation- and replication-associated DNA damage. Proliferation-associated
replication stress, DNA damage, and genetic instability are detectable in CLDs before any neoplastic
changes occur. Accumulated levels of hepatocyte apoptosis determine and predict subsequent hepato-
carcinogenesis. Proliferation-associated DNA damage is sensed by a complex comprising caspase-8,
FADD, c-FLIP, and a kinase-dependent function of RIPK1. This platform requires a non-apoptotic
function of caspase-8, but no caspase-3 or caspase-8 cleavage. It may represent a DNA damage-sensing
mechanism in hepatocytes that can act via JNK and subsequent phosphorylation of the histone
variant H2AX.
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Significance
We identified persistent hepatocyte apoptosis as a universally decisive determinant of HCC development in distinct mouse
models and various human CLDs. Accordingly, levels of hepatocyte apoptosis and DNA damage predict the risk for liver
cancer, the second leading cause of cancer-related death worldwide. Finding that caspase-8 not only executes hepatocyte
apoptosis, but also has a non-apoptotic function in DNAdamage response demonstrates its opposing functions. By orches-
trating DNA damage response as part of the signaling platform, caspase-8 may protect against proliferation-associated ge-
netic instability, and therefore early stages of hepatocarcinogenesis. Whereas once tumors are established, low caspase-8
expression is associatedwith less aggressive behavior of humanHCC.Our data illustrate divergingmechanistic links of cas-
pase-8 to cancer biology.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common primary
malignant liver tumor, the fifthmost prevalent cancer, the second
leading cause of cancer-related death and the fastest rising
cancer worldwide (El-Serag and Kanwal, 2014). HCC arises on
the background of chronic liver diseases (CLDs) such as chronic
hepatitis B virus and hepatitis C virus (HCV) infections, alcohol,
metabolically and dietary-induced fatty liver disease, and steato-
hepatitis, autoimmune, or chronic cholestatic diseases (Forner
et al., 2012). Independent of the underlying etiology, all CLDs
exhibit persistent hepatocyte damage. To maintain liver homeo-
stasis and prevent the accumulation of mutations, damaged he-
patocytes are eliminated by programmed cell death, regulated
by key molecules, including caspase-8 and receptor-interacting
protein kinase 1 (RIPK1) (Luedde et al., 2014). Hepatocyte-spe-
cific knock out of the anti-apoptotic Bcl2-family membermyeloid
cell leukemia 1 (Mcl-1) gene in mice (Mcl-1Dhep mice) recapitu-
lates CLD pathophysiology including severe liver damage and
regeneration early in life (Vick et al., 2009) and subsequent
HCC development (Weber et al., 2010). Here we functionally
and quantitatively examine the interplay between caspase-8-
dependent hepatocyte apoptosis and regeneration-associated
replication stress, genetic instability, and hepatocarcinogenesis.
Moreover, we investigate a role for caspase-8, in conjunction
with other regulators of cell death and inflammation, during
DNA damage recognition within hepatocytes.
RESULTS
CLDs Display High Levels of Hepatocyte Apoptosis, DNA
Damage, Genetic Instability, and Risk for HCC
Hepatocyte apoptosis is an etiology-independent hallmark of
human CLDs (Figures 1A, S1A, and S1B). Increased levels of
apoptosis correlated with increased hepatocyte proliferation,
reflecting regeneration, with significantly higher numbers of cells
positive for the DNA damage marker gH2AX (Figures 1A, S1A,
and S1C–S1F), and with higher expression of DNA damage-
responsive (DDR) genes (Figures S1C and S1D). Liver tissues
from CLD patients further displayed high levels of genetic insta-
bility at chromosomal common fragile sites (CFS) (Gao and
Smith, 2014) as determined by TaqMan copy number assay (Fig-
ures 1B andS1G) and fragment length analysis (Figure 1C). Thus,
our data suggest that genetic instability is established long
before dysplastic changes are detectable. We next looked for
an association between serum transaminase levels (Figure 1D)
(as a surrogate marker for liver cell apoptosis) and subsequent
HCC development. Elevated serum alanine and aspartate trans-
aminase (ALT and AST) levels in CLDswere associated with sub-
sequent HCC development: (1) retrospective analysis of patients
with chronic HCV infection revealed that patients who developed
HCC had significantly higher ALT and AST levels (p < 0.05) during
a period of 6 years preceding HCC diagnosis compared with
HCC-free individuals of the same cohort (matched for model of
end-stage liver disease) score with similar albumin and bilirubin
levels (Figures 1E, 1F, and S1H). (2) Retrospective analysis of
liver transplant (LT) patients revealed that patients transplanted
for HCC had significantly higher ALT and AST levels 1 year prior
to LT compared with patients of the same cohort undergoing
LT for non-HCC indications (p < 0.001; Figure S1I).
Risk for HCC Development Correlates with Levels of
Hepatocyte Apoptosis and DNA Damage Also in Mice
To functionally investigate the role of apoptosis for HCC devel-
opment in vivo, we prospectively monitored Mcl-1Dhep mice for
serum transaminase levels which, similarly to CLD patients, are
characterized by chronically increased hepatocyte apoptosis
and regeneration (Vick et al., 2009). Remarkably, the same
Mcl-1Dhep mice that developed liver tumors at 1 year (50% of
this cohort) also displayed higher serum ALT (and AST, data
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not shown) levels throughout life compared with Mcl-1Dhep mice
without tumor development (Figures 2A–2C). Parallel to a
reduced sensitivity toward tumor necrosis factor (TNF)-mediated
apoptotic signaling with age (Figure S2A), ALT levels dropped
and reached similar levels in both groups after 4 months.
Nevertheless, differences were statistically significant at 2 and
4 months, i.e., the period of high levels of liver damage and
regeneration. Livers of 2-month-old Mcl-1Dhep mice showed a
moderate to high disease activity when applying a standard
human scoring system (Batts and Ludwig, 1995) (Figure 2D). A
statistically significant positive correlation between the percent-
age of cleaved caspase-3+ hepatocytes and serum ALT levels
was also found (Figure 2E). Livers of 2-month-old Mcl-1Dhep
mice revealed increased levels of proliferating hepatocytes and
numbers of gH2AX+ hepatocytes (Figures 2F and 2G), which
positively correlated with ALT levels (Figure 2H), strongly sug-
gesting a link between hepatocyte apoptosis and DNA damage.
Next, mRNA profiling unraveled genes differentially expressed
in livers of 2-month-oldwild-type, homozygous, and hemizygous
Mcl-1Dhep mice, which were verified by qPCR (Figure S2B).
KEGG pathway analysis revealed that genes upregulated by at
least 2-fold were involved in diverse cellular functions including
apoptosis, cell cycle, differentiation, metabolism, and DDR (Fig-
ure 2I). Gene set enrichment analysis revealed that livers of
Mcl-1Dhep mice were not only significantly enriched for genes
related to apoptosis and proliferation, but also to viral infection,
wounding (not shown), alcoholic hepatitis, and, despite being
non-neoplastic, also to HCC (Figure 2J). Collectively, our find-
ings show that Mcl-1Dhep mice are appropriate for investigating
HCC development on a CLD background.
Next, we tested whether increased hepatocyte apoptosis
through tumor necrosis factor receptor 1 (TNFR1) per se deter-
mined hepatocarcinogenesis in Mcl-1Dhep mice, rather than
loss of a non-apoptotic function of Mcl-1. Mcl-1Dhep mice were
crossed with TNFR1-deficient mice (Mcl-1Dhep/TNFR1/ mice)
to inhibit TNFR1-dependent apoptosis and downstream
signaling via TNFR-caspase-8-BID/tBID-Mcl-1. Two-month-old
Mcl-1Dhep/TNFR1/ mice showed lower serum transaminase
activity compared with age-matchedMcl-1Dhep mice (Figure 3A),
and revealed significantly lower numbers of apoptotic and prolif-
erating hepatocytes compared with Mcl-1Dhep mice (Figure 3B).
This was paralleled by significantly increased hepatic mRNA
levels of the death receptors Tnfr1 and Fas in Mcl-1Dhep mice
compared with Mcl-1Dhep/TNFR1/mice, whereas Tnfr2, Trailr,
and the ligands Tnfa, Fasl, and Trail (Figure S3A), and bilirubin
and alkaline phosphatase showed no statistically significant
difference (Figure S3B). Interestingly, livers of Mcl-1Dhep mice,
but not Mcl-1Dhep/TNFR1/ mice, displayed substantial cas-
pase-8 cleavage (Figures S3C and S3D). Similar to LPS/DGal-
challenged wild-type mice treated with the caspase-8 inhibitor
zITED (Figure S3E), Mcl-1Dhep mice treated with zITED also dis-
played significantly decreased ALT levels (and AST, data not
shown) and significantly less hepatocyte apoptosis (Figures
S3F and S3G). In contrast, treating Mcl-1Dhep mice with the cas-
pase-1 inhibitor, YVAD-CMK, used as an off-target control for
zITED, did not affect ALT levels (Figure S3F). Thus, hepatocyte
apoptosis in Mcl-1Dhep mice was caspase-8 dependent.
Remarkably, Mcl-1Dhep/TNFR1/ mice demonstrated a sig-
nificantly reduced tumor incidence at 1 year compared with
Mcl-1Dhep mice (28% versus 50%, p < 0.05; Figures 3C and
3D). In line with the data presented above, those Mcl-1Dhep/
TNFR1/ mice that developed liver tumors also displayed
significantly higher transaminase levels at 2 months (Figure 3E).
Further analyses of the microenvironment of Mcl-1Dhep
livers revealed: (1) no activation of canonical nuclear factor kB
(NF-kB) signaling (Figure S3H), (2), no or only low levels of inflam-
masome activation as determined by cleaved caspase-1 and
cleaved interleukin-1b (IL-1b) levels (Figure S3I and data not
shown), and (3) a significant increase expression of several in-
flammatory cytokines IL6, IL33, and IFNg (with reduced levels
of IL6, IL33, and IFNg in Mcl-1Dhep/TNFR1/ livers; Figure S3J).
Collectively, these findings show that the association between
high apoptotic activity of hepatocytes (in early disease stages)
with subsequent liver cancer development previously described
for CLD patients also exists in Mcl-1Dhep mice. Furthermore,
they suggest that persistently increased hepatocyte apoptosis,
resulting in regenerative proliferation and high DNA replica-
tion rate, determines hepatocarcinogenesis. This hypothesis is
underpinned by stochastic considerations (Figure S4).
Reduced DNA Damage and Genetic Instability upon
Ablation of TNFR1 and Caspase-8
To identify the source of DNA damage and to determine the
level of genetic instability in relation to hepatocyte apoptosis,
we analyzed Mcl-1Dhep mice, and, to exclude Mcl-1-specific
effects, TAK1Dhep mice characterized by increased hepatocyte
apoptosis at 6 weeks and caspase-8-dependent HCC develop-
ment at 35 weeks (100% incidence) (Bettermann et al., 2010).
Co-staining for gH2AX and cleaved caspase-3 revealed that
hepatocytes from 6- to 8-week-old Mcl-1Dhep mice as well as
TAK1Dhep mice which were positive for gH2AX were mostly
negative for cleaved caspase-3. Thus, gH2AX-positivity was
unlikely to be a consequence of apoptosis of individual hepato-
cytes (Figure 4A). Immunofluorescence (IF) staining for gH2AX
Figure 1. DNA Damage and Genetic Instability CLDs Preceding Neoplastic Lesions and HCC
(A) Apoptosis (cl.Casp3), proliferation (Ki67), and DNA damage (gH2AX) in human CLDs of different etiology (viral hepatitis: hepatitis B virus [HBV] and [HCV],
metabolic [NASH], and autoimmune [AIH] diseases). Arrowheads indicate cells with positive IHC staining. Scale bars, 100 mm.
(B) TaqMan copy number assay for allelic imbalances (AI). Each square represents one area of microdissected tissue, lines indicate different areas of the same
liver (red, AI; black, no AI; NT, non-tumor CLD tissue).
(C) Fragment length analysis (loci DS31263 and DS31289) in CLD tissues. Arrowheads indicate changes in fragment length distribution.
(D) Serum ALT levels in CLDs (n = 4 HBV, n = 8 HCV, n = 4 NASH, and n = 4 AIH).
(E and F) Serum ALT levels in patients with HCC versus without HCC of the same cohort (n = 13 in both groups). (E) Time course 6 years prior to diagnosis and (F)
mean of ALT values over time.
In (D), (E), and (F), data are presented as mean ± SEM. Statistical significance was calculated using Fisher’s exact test (B), ANOVA with Bonferroni correction (D),
or Student’s t test (E and F). *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S1.
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Figure 2. Risk of HCC Development Correlates with Apoptosis and DNA Damage in Mcl-1Dhep Mice
(A) Livers from 12-month-old mice. Arrowheads indicate a tumor. Scale bar, 1 cm.
(B) Serum ALT levels throughout life time of wild-type mice, Mcl-1Dhep mice that developed HCC at 12 months (n = 12), and Mcl-1Dhep mice that did not.
(C) Serum ALT levels at 2 months (n = 8 animals per group).
(D) Hepatocyte death rates (n = 20).
(E) Correlation of ALT levels with hepatocytes apoptosis (n = 15).
(F) Hepatocyte mitosis (upper square and insert), apoptosis (lower square and insert), and signs of DNA damage (gH2AX, black arrow) in livers of Mcl-1Dhep mice.
Scale bars, 50 mm.
(G) gH2AX+ hepatocytes per high-power field (HPF) in wild-type (n = 7) and Mcl-1Dhep mice (n = 12).
(H) Correlation of ALT levels with the number of gH2AX+ hepatocytes (n = 11).
(legend continued on next page)
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and Ki67 of livers from 6- to 8-week-old mice revealed virtually
no gH2AX+ hepatocytes in wild-type livers, whereas Mcl-1Dhep
and TAK1Dhep hepatocytes displayed the typical nuclear staining
pattern and substantial gH2AX/Ki67 double positivity (10%
and 20%, respectively; Figures 4B and 4C).
To further investigate hepatocyte apoptosis, DDR, and ge-
netic instability in relation to hepatocarcinogenesis, Mcl-1Dhep/
TNFR1/mice and crossings of TAK1Dhep mice were analyzed:
TAK1Dhep/RIPK3/ mice (devoid of necroptosis, HCC-prone),
and TAK1Dhep/Casp8Dhep mice (devoid of apoptosis, not HCC-
prone; Table S1) (Vucur et al., 2013). The percentage of Ki67+/
gH2AX+ hepatocytes was significantly reduced in intercrossings
with reduced apoptosis (Mcl-1Dhep/TNFR1/ < Mcl-1Dhep mice;
and TAK1Dhep/Casp8Dhep < TAK1Dhep < TAK1Dhep/RIPK3/
mice, respectively; Figures 4B and 4C). Similarly, intercross-
ings with increased HCC burden also displayed an increased
percentage of Ki67+/gH2AX+ hepatocytes (Mcl-1Dhep >
Mcl-1Dhep/TNFR1/mice; and TAK1Dhep/RIPK3/ > TAK1Dhep/
Casp8Dhep > TAK1Dhep mice, respectively; Figures 4B and 4C).
The activation of DNA repair pathways in regenerative murine
livers was further corroborated by western blot analysis and
expression analysis of genes related to DNA replication, DDR,
and DNA repair. Again, mRNA expression of DDR-related
genes (and associated protein modifications) were reduced in
parallel with hepatocyte apoptosis levels (Figures S5A–S5C). In
contrast to wild-type mice, livers of Mcl-1Dhep, TAK1Dhep, and
TAK1Dhep/RIPK3/ mice showed widespread allelic imbal-
ances (AI) at CFS, demonstrating genetic instability in hyper-
apoptotic and hyper-proliferative mouse livers. Of note, although
higher compared with wild-type mice, AI rates were much
lower in Mcl-1Dhep/TNFR1/ mice and TAK1Dhep/Casp8Dhep
mice (Figure 4D).
Since almost all gH2AX+ hepatocytes were proliferating
(Ki67+), replication stress (single-stranded DNA breaks accu-
mulation and replication fork stalling) was considered the most
likely source of DNA damage (Halazonetis et al., 2008). This
was corroborated by fluorescence-activated cell-sorting anal-
ysis showing significantly less gH2AX+/RPA+ hepatocytes in
low proliferating livers (Figure S5D). Treating Mcl-1Dhep and
TAK1Dhep mice with the antioxidants, butylated hydroxyanisole
or vitamin E, for 4 weeks revealed no evidence for reactive oxy-
gen species being a major inducer of DNA damage in these mice
(Figures S5E–S5H).
Hyper-proliferation-Associated Replicative Stress in
Regenerating Livers Causes DNA Damage
Next, to test whether proliferation by itself, i.e., independent of
hepatocyte apoptosis, was sufficient to trigger DNA damage,
we performed partial hepatectomy (PHX). Whereas low levels
of baseline proliferation in wild-type mice were not associated
with detectable levels of DNA damage, western blot analysis
and immunohistochemistry for gH2AX peaked at 48 hr post-
PHX, i.e., long after evidence for apoptosis (Speicher et al.,
2014), and parallel to the proliferative activity (Figures 5A–5G).
The correlation between hepatic hyper-proliferation and DNA
damage was confirmed by gH2AX/bromodeoxyuridine (BrdU)
double staining. Almost all gH2AX+ hepatocytes had incorpo-
rated BrdU, indicating that DNA damage occurred in replicating
hepatocytes. To further investigate whether gH2AX in prolifer-
ating hepatocytes was marking DNA breakage, beside replica-
tion stress per se, pulse field gel electrophoresis (PFGE) was
performed showing DNA double-strand breaks (DSB) in livers
48 hr after PHX (Figure 5F).
To test if hyper-proliferation-associated replication stress
also occurs in human livers, biopsies of patients after ALPPS
(associating liver partition and portal vein ligation for staged
hepatectomy) procedure were analyzed (Schadde et al., 2014).
Biopsies taken post-liver partition and portal vein ligation from
the patients’ highly regenerating left lobe revealed significantly
elevated numbers of Ki67+ hepatocytes and a substantial num-
ber of Ki67+/gH2AX+ hepatocytes. The latter were significantly
lower prior to ALPPS, and in the non-regenerating right liver
lobe that had been de-portalized (Figures S6A and S6B). Thus,
replication stress due to increased proliferation also occurs in
regenerating human livers.
Next, we aimed to investigate whether replication stress and
the associated DNA DSBwere determinedmainly by hepatocyte
proliferation, or also directly affected by TNFR1, caspase-8, or
RIPK3. To this end, we analyzed livers of TNFR1/2/, RIPK3/,
and Casp8Dhep mice 48 hr post-PHX. Whereas similar levels of
Ki67+/gH2AX+ hepatocytes (between 25% and 35%) were de-
tected in livers of wild-type, TNFR1/2/, and RIPK3/ mice,
unexpectedly <10% of hepatocytes from livers of Casp8Dhep
mice were Ki67+/gH2AX+ (Figures 5H and 5I). Notably, at the
same time PFGE clearly demonstrated DSB in Casp8Dhep mice
(Figures 5J and 5K), suggesting that caspase-8 plays an impor-
tant role in sensing or mediating DNA replication-associated
damage in hyper-proliferating hepatocytes.
Phosphorylation of Histone H2AX Is Impaired in
Caspase-8-Deficient Hepatocytes
We then sought to determinewhether caspase-8 also plays a role
in mediating or sensing DNA DSB not related to hyper-prolifera-
tion. To this aim, wild-type and Casp8Dhep mice were treated
with non-hepatotoxic doses of the genotoxic agent doxorubicin
(Yang et al., 2014). Post-application (12 hr), wild-type mice dis-
played strong gH2AX reactivity in the liver (Figures 6A, 6B, S7A,
and S7B) and other tissues (Figure S7C). Strikingly, although
PFGEdisplayedDNADSB in livers ofCasp8Dhepmice (Figure 6B),
Casp8Dhep hepatocytes were negative for gH2AX, whereas
gH2AX+ nuclei were still detectable in Kupffer cells and several
other caspase-8-proficient cell types (Figures 6A and S7C and
datanot shown). Post-doxorubicin treatment, noapoptotic hepa-
tocytes, no cleavage of caspase-8 above baseline levels (Figures
S7D–S7G), or no elevated transaminase levels were detectable
(Figure S7H). Thus, H2AX phosphorylation under caspase-8 defi-
ciency is impaired also following doxorubicin-induced DNA
damage.
(I) Pie chart displaying the percentage of genes at least 2-fold upregulated in Mcl-1Dhep mice and clustered according to KEGG pathway database analysis.
(J) Gene set enrichment analysis comparing all differentially regulated genes from Mcl-1Dhep mice with various gene sets. NES, normalized enrichment score.
In (B) and (C), data are presented as mean ± SEM. In (G), the bar indicates the mean. Statistical significance was calculated using Student’s t test (B and G),
ANOVA with Bonferroni correction (C). *p < 0.05. See also Figure S2.
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The Catalytic Activity of Caspase-8 Is Dispensable for
H2AX Phosphorylation
Pre-treating wild-type mice with the pan-caspase inhibitor QVD-
OPH did not abrogate H2AX phosphorylation after doxorubicin
application (Figure 6A). In contrast, QVD-OPH strongly reduced
liver damage in mice co-treated with LPS/DGal (Figures S7F–
S7H). To exclude incomplete inhibition of caspase-8 activity us-
ing QVD-OPH, knockin mice expressing an uncleavable mutant
Figure 3. Reduced Apoptosis, Proliferation, and Tumor Development in Mcl-1Dhep/TNFR1–/– Mice
(A) AST and ALT levels from 2-month-old Mcl-1Dhep (n = 16), Mcl-1/TNFR1/ (n = 10), and wild-type (n = 8) mice.
(B) Staining and quantification for H&E, cl.Casp3, and Ki67 in 2-month-old wild-type, Mcl-1Dhep/TNFR1/, and Mcl-1Dhep mice. Arrowheads indicate cells with
positive IHC staining. Scale bars, 100 mm.
(C) Macroscopy, H&E, and collagen IV staining of livers at 12 months of age. The arrowhead indicates a tumor. Scale bars, 100 mm.
(D) Tumor development after 12 months in Mcl-1Dhep mice (n = 44) compared with Mcl-1Dhep/TNFR1/ mice (n = 39).
(E) Retrospective analysis of tumor development and correlation to ALT levels in the serum of 2-month-old mice (n = 11 Mcl-1Dhep/TNFR1/mice without HCC,
n = 5 with HCC).
In (A), (B), (D), and (E), data are presented as mean ± SEM. Statistical significance was calculated using Student’s t test (A and B), ANOVA with Bonferroni
correction (E), or Fisher’s exact test (D). *p < 0.05; **p < 0.01; ***p < 0.001; n.s., not significant. See also Figures S3 and S4.
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Figure 4. Reduced DNA Damage And Genetic Instability in Mcl-1Dhep/TNFR1–/– and TAK1/Casp8Dhep Mice and Intercrossings
(A) Staining for gH2AX (black) and cleaved Casp3 (red), double-positive hepatocytes (black/red arrows). Scale bar, 50 mm.
(B) IF staining for gH2AX and Ki67 in wild-type, Mcl-1Dhep, and Mcl-1Dhep/TNFR1/mice, as well as TAK1Dhep, TAK1/Casp8Dhep, and TAK1Dhep/RIPK3/mice.
Arrowheads indicate cells with positive IF staining. Scale bar, 10 mm.
(C) Quantification of Ki67+ and Ki67+/gH2AX+ hepatocytes (n = 4 mice per group, n = 5 for Mcl-1Dhep mice).
(D) Rate of AI in wild-type, Mcl-1Dhep, and Mcl-1Dhep/TNFR1/ mice, TAK1Dhep, TAK1Dhep/RIPK3/, and TAK1/Casp8Dhep mice (TaqMan copy number assay,
each square represents one area of microdissected liver tissue, lines indicate different areas of the same liver; red, AI; black, no AI). Mcl-1Dhep mice and in-
tercrossings at 2 months; TAK1Dhep mice and intercrossings at 6 weeks of age.
In (C), data are presented asmean ± SEM. Statistical significance was calculated using ANOVAwith Bonferroni correction (C), or Fisher’s exact test (D). *p < 0.05;
**p < 0.01; ***p < 0.001. See also Figure S5.
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Figure 5. Detection of Proliferation-Associated DNA Damage after PHX Is Impaired in Casp8Dhep Mice
(A–C) Western blot analysis of whole-liver lysates (A), immunostainings (B), and quantification of gH2AX+ hepatocytes 0, 6, 24, and 48 hr post-PHX (C). Scale
bar, 50 mm.
(D and E) BrdU incorporation combined with gH2AX staining (n = 4). Scale bar, 10 mm.
(F and G) PFGE with densitometric quantification to visualize DNA DSB in livers of wild-type mice after PHX (n = 3).
(H and I) IF staining (H) and quantification of Ki67+/gH2AX+ hepatocytes in wild-type, TNFR1/2/, RIPK3/, and Casp8Dhep mice (I). Arrowheads indicate cells
with positive IF staining. Scale bar, 10 mm.
(J and K) PFGE with densitometric quantification to visualize DNA DSB in livers of Casp8Dhep mice after PHX.
In (C), bar represents mean. In (E), (G), (I), and (K) data are presented as mean ± SEM. In (G), bar indicates the mean. Statistical significance was calculated using
ANOVA with Bonferroni correction (C and I) or Student’s t test (E, G, and K). *p < 0.05; **p < 0.01; ***p < 0.001; n.s., not significant. Irrelevant bands were omitted
from gels (F and J). Areas in which lanes were omitted are indicated by white space between lanes. See also Figure S6.
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of caspase-8 (D387A) were also treated with doxorubicin (Kang
et al., 2008). Similar to wild-type mice, caspase-8 D387-mutant
mice revealed gH2AX positivity in hepatocytes upon doxorubicin
treatment (Figure 6C). Consistent with results from conditional
caspase-8 knockout mice, we observed significantly reduced
gH2AX positivity in Casp8//RIPK3/ livers 12 hr post-treat-
ment (Figure 6D). In contrast, hepatocytes from RIPK3/ litter-
mates were positive for gH2AX, consistent with hepatocytes
upon PHX of RIPK3/ mice (Figure 5H). Collectively, these
data show that full-length caspase-8, but not its cleaved form
or catalytic activity, is required for H2AX phosphorylation.
H2AX Phosphorylation Is Impaired in Hepatocytes
Deficient of c-FLIP, FADD, or RIPK1 Kinase Activity
We next investigated whether caspase-8-interacting proteins
were involved in H2AX phosphorylation. Doxorubicin-induced
H2AX phosphorylation was not affected in TNFR1/2/ mice,
indicating that hepatic H2AX phosphorylation activated by
low levels of DNA DSB is not executed by TNFR1/2 signaling
complexes. In contrast, c-FLIP-deficient hepatocytes lacked
gH2AX positivity post-doxorubicin treatment (Figures 6D and
6E), pointing to a crucial role of the c-FLIP/Casp8 dimer in
DDR. Pharmacological inhibition of RIPK1 by pre-treatment of
wild-type mice with necrostatin-1 (Nec1) did not prevent DNA
DSB formation, but prevented the appearance of gH2AX+ hepa-
tocytes upon doxorubicin treatment (Figures S7A and S7B).
This indicated a role of RIPK1 for H2AX phosphorylation in vivo.
Since Nec1 blocks both RIPK1 assembly and RIPK1 kinase
function, we analyzed knockin mice expressing a kinase-inacti-
vated RIPK1 mutant (RIPK1KD mice) and observed significantly
impaired H2AX phosphorylation, demonstrating that the kinase
activity of RIPK1 is required for H2AX phosphorylation (Fig-
ure 6D). In addition, mice deficient for RIPK1, RIPK3, and
FADD (R1//R3//FADD/ mice), as well as RIPK1 (haplo-
deficient), RIPK3, and FADD (R1+//R3//FADD/ mice), also
demonstrated impaired H2AX phosphorylation. Since RIPK3
was not involved in DDR and haploinsufficiency is not reported
for RIPK1 (Dillon et al., 2014), the lack of gH2AX+ cells in
R1+//R3//FADD/ mice was most likely due to the dele-
tion of FADD. Of note, mice deficient for X-linked inhibitor of
apoptosis protein (XIAP/) clearly showed H2AX phosphoryla-
tion upon doxorubicin treatment (Figure S7A). In summary,
RIPK1KD, Casp8//RIPK3/, R1//R3//FADD/, R1+//
R3/FADD/, and c-FLIPDhep mice all showed a significantly
reduced percentage of gH2AX+ foci in hepatocyte nuclei.
Caspase-8 Functions within a Multi-Protein Complex to
Orchestrate H2AX Phosphorylation
To testwhether a caspase-8-containing protein complex forms in
response toDNADSB,U2OScellswere treatedwithdoxorubicin,
followed by time-course immunoprecipitation experiments with
an anti-caspase-8 antibody. Starting 30 min post-treatment
and peaking at 1 hr, RIPK1was co-immunoprecipitatedwith cas-
pase-8, FADD (Figure 6F, red box), and c-FLIP (Figure S7I, red
box). In parallel, gH2AX positivity was detectable starting 1 hr
post-doxorubicin treatment. Of note, complex formation 1 hr
post-doxorubicin treatment was independent of any apoptotic
activity, which was, however, observed between 4 hr (PARP
cleavage) and 18–24 hr (caspase-3 cleavage) post-doxorubicin
treatment (Figures 6F and 6G, blue boxes). Importantly, absolute
quantification of caspase-8, FADD, c-FLIP, and RIPK1 in cas-
pase-8 immunoprecipitates was performed 1 hr post-doxoru-
bicin treatment by a mass spectrometry-based AQUA method
(Schleich et al., 2015). This revealed a significant amount of
FADD and RIPK1 in complex with caspase-8 in doxorubicin-
treated cells (Figure S7J).
Since the linear ubiquitin chain assembly complex (LUBAC)
plays a role in preventing cell-death-inducing complex forma-
tion in various cell types including hepatocytes (Lafont et al.,
2017; Shimizu et al., 2017), it was considered a candidate
signaling event. Indeed, LUBAC components HOIP, HOIL-1,
and SHARPIN, as well as the inhibitor of apoptosis proteins
(IAP) cIAP1, cIAP2, and XIAP, known to negatively regulate for-
mation of the ripoptosome (Tenev et al., 2011), were transiently
reduced 15 to 30 min post-doxorubicin treatment of U2OS cells
(Figure 6H).
Next, we tested whether complex formation in response to
DNA damage was paralleled by a change in subcellular local-
ization. Western blot analysis after subcellular fractionation
displayed a proportion of RIPK1, caspase-8, and c-FLIP in the
Figure 6. Caspase-8, RIPK1, FADD, and c-FLIP Are Crucial for Phosphorylation of H2AX in Hepatocytes upon Doxorubicin Treatment
(A) IF for gH2AX in untreated wild-type mice and wild-type, Casp8Dhep, and QVD-OPH-treated wild-type mice following doxorubicin treatment. Arrow heads
illustrate gH2AX+ foci in nuclei. Scale bar, 10 mm.
(B) PFGE on livers of doxorubicin-treated mice.
(C) gH2AX staining of doxorubicin-treated wild-type and caspase-8 D387-mutant mice. Scale bar, 50 mm.
(D) gH2AX IF staining 12 hr post-doxorubicin-induced DNA damage in hepatocytes of Casp8//RIPK3/ mice (n = 5), RIPK3/ mice (n = 4), RIPK1KD mice
(n = 9), RIPK1/RIPK3/FADD/ (labeled as R1/R3/FADD/, n = 2), RIPK1+/RIPK3/FADD/ (labeled as R1+/R3/FADD/, n = 2), c-FLIPDhep
(n = 6), and TNFR1/2/ mice (n = 6). Arrowheads illustrate gH2AX+ foci in nuclei. Scale bar, 10 mm.
(E) Quantification of IF stainings (A and D).
(F) Immunoprecipitation with anti-caspase-8 antibody (upper panel) and immunoblotting of lysates (lower panel), 0–24 hr after doxorubicin (5 mM) treatment.
Red box: RIPK1, FADD, and caspase-8 interaction at 1 hr; blue boxes: low-level activation of apoptosis starting at 4 hr post-treatment. (The signal visible in the t =
0 column, cl.PARP lane, does not originate from cl.PARP, but from a lower unspecific band.) Control cells treated for 1 hr with CD95L/FasL (B, beads; L, lysates).
(G) Immunoblotting of lysates, 0–24 hr after doxorubicin (5 mM) treatment looking at levels of total and cl.PARP, blue boxes (F and G): low-level activation of
apoptosis starting at 4 hr post-treatment.
(H) Levels of LUBAC (HOIP, HOIL-1, and SHARPIN), cIAP1, cIAP2, and XIAP in U2OS cells at 15 min (red box) post-doxorubicin stimulation (5 mM).
(I) Subcellular fractionation of U2OS cells.
(J) RIPK1 and gH2AX IF staining in U2OS cells after doxorubicin treatment. The arrowhead indicates colocalizing signals. Scale bar, 10 mm.
Statistical significance was calculated using ANOVAwith Bonferroni correction (E). ***p < 0.001. Irrelevant bands were omitted from gels (B). Areas in which lanes
were omitted are indicated by white space between lanes. See also Figure S7.
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nuclear fraction under steady-state conditions, but no enrich-
ment upon doxorubicin-induced DNA damage (Figure 6I). Local-
ization studies by IF staining and confocal imaging of U2OS cells,
with and without doxorubicin, confirmed the induction of nuclear
gH2AX positivity, while a minor fraction of RIPK1 was already
detectable in the nucleus under steady state (Yoon et al.,
2016). However, no increased nuclear signal was observed after
doxorubicin treatment (Figure 6J).
JNK Is a Downstream Mediator of Caspase-8- and
RIPK1-Dependent H2AX Phosphorylation in
Hepatocytes
To identify candidate downstream signaling pathways of the
DNA damage-sensing platform in hepatocytes, livers of doxoru-
bicin-treated wild-type mice were analyzed for activation of
ATM/ATR targets CHK1 and CHK2 (Figures 7A, S8A, and S8B
and data not shown). Remarkably, no pCHK1+ or pCHK2+ hepa-
tocytes were found 12 hr following doxorubicin-induced DNA
damage, suggesting that the ATM and ATR kinase activity is
rather low at that time, and pointing to DNA damage-trans-
ducing pathways other than ATM and ATR signaling. As control,
LPS/DGal-induced cell death was associated with pCHK1+ and
pCHK2+ apoptotic hepatocytes (Figure S8B). Furthermore, wild-
type mice displayed pcJUN+ hepatocytes upon doxorubicin-
induced DSB, indicative of activated c-JUN N-terminal kinase
(JNK) signaling (Figures 7A and S8A). Of note, hepatocytes of
Casp8Dhep, RIPKKD, Nec1-treated, c-FLIPDhep, and Casp8//
RIPK3/mice all lacked substantial pcJUN staining after doxo-
rubicin treatment, in contrast to QVD-OPH-treated wild-type,
TNFR1/2/, RIPK3/, and XIAP/mice (Figures S8A and
S8B). Co-IF staining for pJNK and gH2AX revealed that wild-
type hepatocytes (independent of QVD-OPH pre-treatment)
and TNFR1/2/ hepatocytes had distinct nuclear pJNK signals
following doxorubicin treatment, which partially co-localized
with gH2AX signals, suggesting JNK as the responsible kinase
for H2AX phosphorylation. Casp8Dhep, RIPK1KD, and c-FLIPDhep
hepatocytes were mostly devoid of pJNK signals (Figure 7B),
suggesting that JNK signaling is downstream of the kinase func-
tion of RIPK1, and of caspase-8, FADD, and c-FLIP, and, as
such, is involved in H2AX phosphorylation (Picco and Pages,
2013). Furthermore, mice lacking both JNKs in hepatocytes
(JNK1/2Dhep mice) displayed DNA DSB by PFGE, but lacked
gH2AX+ hepatocytes after doxorubicin treatment (Figures 7C
and 7D). At the same time, PFGE displayed DNA DSB in livers
of JNK1/2Dhep mice (Figure S8C).
JNK Is a Downstream Mediator of Caspase-8- and
RIPK1-dependent DDR Also in Cell Types Other than
Hepatocytes
To determine whether caspase-8 and JNK were involved
in H2AX phosphorylation in non-hepatocytic cells, caspase-8
was knocked down in U2OS cells. As expected, shCASP8
lentivirus-transfected U2OS cells were less sensitive to TNF-
a-mediated apoptosis comparedwith shCTRLcells (Figure S8D).
As observed in vivo, shCTRL cells also displayed a clear increase
in gH2AX 30 min post-doxorubicin administration and a strong
pJNK signal, but no obvious ATM or ATR activation (Figure 7E).
Strikingly, upon doxorubicin treatment, knock down of cas-
pase-8 substantially decreased gH2AX, pJNK, and pcJUN in
shCASP8 cells compared with shCTRL cells (Figures 7E and
S8E). Pre-treatment of shCTRL cells with a JNK inhibitor
(JNKi), but not with an ATM inhibitor (ATMi), abolished c-JUN
activation and decreased H2AX phosphorylation similar to
shCASP8 cells (Figure 7E, red boxes). Combining ATMi and
JNKi reduced gH2AX signals in shCASP8 cells, and led to mini-
mal activation of ATR (Figure S8E). To exclude that data were
cell line-specific, HepG2 cells were analyzed, revealing a cas-
pase-8- and JNK-dependent gH2AX increase 30min post-doxo-
rubicin administration (Figure S8F, red boxes).
Next, we analyzed potential downstream targets of the
caspase-8-containing complex regulating H2AX phosphoryla-
tion. Of note, IF staining for p53-binding protein 1 (53BP1), an
important regulator of the cellular response to DNA DSB
(Panier and Boulton, 2014), revealed that, in response to doxo-
rubicin treatment, 53BP1 nuclear positivity was absent in
shCASP8 cells, similar to gH2AX 30 min following doxorubicin
treatment (Figure S8G). This indicated impaired recruitment
of 53BP1 to sites of DNA DSB under caspase-8 deficiency.
Aiming to identify further signaling pathways involved in
caspase-8-dependent H2AX phosphorylation, we analyzed
MAPK and phosphatidylinositol 3-kinase signaling pathways.
We found reduced activation of p38 and ERK1/2 under
steady-state conditions in shCASP8 cells. At the same time
total levels of ERK1/2 and also AKT2 were increased (Fig-
ure S8H, red boxes). Doxorubicin treatment induced activation
of ERK1/2 and AKT2, whereas p38 activation was impaired in
shCASP8 cells. Thus, caspase-8 interferes with or controls
MAPK signaling under steady-state and doxorubicin-chal-
lenged conditions. Looking for an interaction between JNK
and gH2AX in human livers, we found mostly overlapping sig-
nals for pJNK and gH2AX in liver tissues of patients with
chronic low-level, CLD-related liver regeneration and acute
high-level liver regeneration after ALPPS, indicating a role of
JNK in mediating DDR (Figure 8A).
Finally, we analyzed publically accessible databases to
address whether caspase-8 expression affects HCC biology.
Although different datasets yielded variable results, analysis of
the largest, most stringent cohort (n = 358 patients) from The
Cancer Genome Atlas data portal, validated by the Universal
exPression Codes method, revealed that HCC with low cas-
pase-8 expression levels were associated with a better overall
survival compared with HCC with high caspase-8 expression
(Figure 8B). Moreover, high caspase-8 expression correlated
with high PCNA and Ki67 expression (PCNA versus CASP8:
p = 2 3 1022, Ki67 versus CASP8: p = 3 3 1025; data not
shown), indicating high proliferative activity. Finally, HCC with
methylation of the caspase-8 gene exhibited a better overall sur-
vival compared with caspase-8-unmethylated HCC (Figure 8C).
These findings suggest that low caspase-8 expression is associ-
ated with a less aggressive behavior of HCC.
DISCUSSION
Hepatocyte apoptosis, a hallmark of CLDs, plays opposing roles
in liver homeostasis: on the one hand, it constitutes a hepato-
protective mechanism by eliminating damaged hepatocytes.
On the other hand, chronically increased hepatocyte apoptosis
is harmful.
Cancer Cell 32, 342–359, September 11, 2017 353
Figure 7. JNK Is a Downstream Mediator of Caspase-8-, c-FLIP-, and RIPK1-Dependent Phosphorylation of H2AX In Vivo and In Vitro
(A) Immunohistochemistry for pCHK1, pCHK2, and pcJUN in livers after doxorubicin treatment. Arrowheads indicate pcJUN-positive nuclei. Scale bar, 50 mm.
(B) gH2AX and pJNK co-stainings of livers 12 hr post-doxorubicin treatment. Merged: overlay of DAPI, gH2AX, and pJNK staining. Arrowheads indicate IF signals
for gH2AX (green), pJNK (red), or overlapping signals of both (yellow). Scale bar, 10 mm.
(C and D) IF stainings (C) and quantification for gH2AX in wild-type and JNK1/2-deficient hepatocytes 12 hr post-doxorubicin treatment (D). Arrowheads indicate
IF signals for gH2AX. Scale bar, 10 mm.
(E) Analysis of DDR signaling by western blotting of lysates from doxorubicin-treated caspase-8 knockdown cells, JNK inhibitor (SP600125) and ATM inhibitor
(KU-55933) pre-treated control cells (U2OS). Red boxes: differences in gH2AX and pJNK activation post-doxorubicin treatment between control cells and
lentiviral caspase-8 knockdown and JNK inhibitor treated cells. Statistical analysis was corrected for three tests using the Bonferroni method. See also Figure S8.
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Here, we show that persistently increased levels of hepatocyte
apoptosis tightly correlate with subsequent HCC development:
(1) CLDpatients who developedHCChad higher preceding trans-
aminase levels compared with case-control matched pairs. (2)
Mcl-1Dhep mice and Mcl-1Dhep/TNFR1/ mice that developed
liver tumors had higher levels of transaminase activity early in
life compared with littermates without tumors. (3) Genetically
reducing apoptosis in Mcl-1Dhep mice, by additional deletion of
TNFR1 (here) orBAK (Hikita et al., 2012), decreased tumorigenesis
similar to TAK1Dhep mice with additional caspase-8 (apoptosis)
but not RIPK3 (necroptosis) deficiency (Vucur et al., 2013).
Collectively, these data identify chronically increased hepatocyte
apoptosis as a major risk for subsequent HCC development.
By demonstrating (1) increased gH2AX+ hepatocytes, indica-
tive of DDR, in both hyper-apoptotic, hyper-regenerating livers
of CLD patients and CLD mouse models, and (2) a significant
level of AI at CFS in these same livers, we link chronically
increased hepatocyte apoptosis with HCC development. Liver
regeneration results in DNA replication stress, making hepato-
cyte proliferation a genotoxic stimulus inducing DNA damage
and genetic instability. DNA replication is a major genotoxic
stress due to the risk of nucleotide misincorporation, the intrinsic
fragility of replicating chromosomes, and the abundance of
repetitive and unusual DNA structures in particular at CFS.
Genome stability pathways address these challenges and mini-
mize replication-associated risks, but require extra time in cell
cycle progression and are often limited in hyper-proliferative
states (Halazonetis et al., 2008).
Our findings in human CLD and murine CLD models, under-
pinned by stochastic considerations (Figure S4), argue that
persistently increased hepatocyte apoptosis resulting in regen-
erative proliferation and high DNA replication rate (independent
of etiology) is a decisive determinant of hepatocarcinogenesis.
This is in line with a recent report on the carcinogenic effect of
replication errors stochastically occurring in highly proliferative
stem cells (Tomasetti and Vogelstein, 2015). This concept also
explains most HCC epidemiological data, i.e., that CLD patients
are at risk to develop HCC, and that the risk increases with dis-
ease activity and duration.
Dissecting the role of caspase-8 for hepatocyte apoptosis,
we discovered a non-apoptotic function of caspase-8 in H2AX
phosphorylation. Firstly, by performing PHX in C57BL/6 and
Figure 8. Evidence for JNK-Dependent DDR in Human Regenerating Livers and Caspase-8 in Human HCC
(A) gH2AX and pJNK co-stainings demonstrating JNK-dependent phosphorylation of H2AX in liver tissue of CLD patients or the left lobe of patients after (right)
portal vein ligation and liver transection (PVL/LT). Arrowheads indicate IF signals for gH2AX (green), pJNK (red), or overlapping signals of both (yellow). Scale
bar, 10 mm.
(B) Overall survival of HCC patients depending on HCC caspase-8 expression level (<mean+1SD; n = 307 patients; >mean+1SD; n = 51 patients, log rank test,
statistical analysis was corrected for three tests using the Bonferroni method. The Cancer Genome Atlas [TCGA] cohort).
(C) Overall survival of HCC patients depending on HCC caspase-8 methylation status (n = 358 patients, TCGA cohort, log rank test).
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Casp8Dhep mice, we show that caspase-8 is needed for an effi-
cient DDR to replication stress. Secondly, we found that doxoru-
bicin-induced H2AX phosphorylation in mice was not deficient in
livers pretreated with the pan-caspase inhibitor (QVD-OPH), or
livers of caspase-8 D387A mutant mice (Kang et al., 2008), but
in mice that were full knockout for caspase-8. Thus, DDR was
not dependent on caspase-8 catalytic activity, but rather on a
non-apoptotic, e.g., a scaffold function of caspase-8. Aiming
to identify caspase-8-interacting molecules, we discovered a
signaling platform comprising also RIPK1, FADD, and c-FLIP.
These molecules are also central in a complex which assembles
independently of death receptor activation, referred to as the
ripoptosome (Tenev et al., 2011). It acts cooperatively in different
combinations: (1) to control cell fate upon genotoxic stress in
concert with NEMO (Biton and Ashkenazi, 2011), (2) together
with RIPK3 to control the non-canonical inflammasome acti-
vation (Kang et al., 2013), (3) together with RIPK1 to control
TNF-a expression NF-kB independently via JNK (Christofferson
et al., 2012), and together with caspase-3 to suppress necrosis
(Brown et al., 2015). Moreover, (4) a different complex, the
PIDDosome (Tinel and Tschopp, 2004), is activated by ATM
and executes apoptosis in response to DNA damage (Ando
et al., 2012). Finally, (5) it was demonstrated recently that a struc-
tural (rather than enzymatic) function of these signaling complex
is central for the production of chemotactic cytokines (Hartwig
et al., 2017; Henry and Martin, 2017). Although not providing a
direct proof of their regulatory function, the downregulation of
LUBAC components and IAPs occurring in temporal association
with the formation of the complex discovered here is remarkable.
It is reminiscent of the formation of the above-mentioned related
complexes. Collectively, findings from all these studies sug-
gest that a defined set of molecules constitutes a dynamic and
temporary signaling platform. This platform integrates various in-
puts (e.g., genotoxic stress, inflammatory signals) resulting in
different outputs (e.g., cell death, cytokine production, DDR),
thus efficiently coordinating cell fate. We consider the com-
plex found in this study to represent one possibility of these re-
sponses, most likely to DNADSB. Although we found no obvious
nuclear localization after induction of DNA damage, our observa-
tions do not preclude that under steady state a minor nuclear
fraction of the above described components remains func-
tionally activatable to form a complex, as described elsewhere
(Yoon et al., 2016).
We observed (1) impaired pJNK and pcJUN response to
doxorubicin in caspase-8-deficient cells, (2) impaired H2AX
phosphorylation after pharmacological inhibition of JNK in
various cell lines (U2OS, HepG2) in response to doxorubicin,
and (3) impaired H2AX phosphorylation in doxorubicin-treated
livers of JNK1/2Dhep mice, all implicating a possible involvement
of JNK signaling. However, performing several in vivo, ex vivo,
and in vitro experiments to investigate the downstream signaling
modes of this pathway did not give conclusive results. The
co-localization of pJNK and gH2AX in human and murine
hepatocyte nuclei suggested a link between pJNK and H2AX
phosphorylation, in line with previous reports (Picco and Pages,
2013). Moreover, activation of the ATM/ATR and JNK signaling
in human and murine CLDs suggested that all pathways
might be present. In contrast, doxorubicin-induced DNA DSB
appeared to preferably activate the JNK signaling pathway,
whereas the ATM/ATR signaling pathway was activated less in
a model- and time-dependent fashion. This inter-experimental
variation made it challenging to clearly demonstrate whether
or not the ATM/ATR signaling was generally activated by the
caspase-8/RIPK1/c-Flip/FADD pathway. Due to the different
kinetics in in vivo and also in distinct in vitro model systems, a
uniform pattern of ATM/ATR activation was not identifiable.
Interestingly, combined use of ATM and JNK inhibitors led
to the strongest and most consistent effects in suppressing
H2AX phosphorylation upon doxorubicin in vitro. Thus, we
conclude that (1) doxorubicin might not necessarily reflect the
overall in vivo signaling behavior of the complex (e.g., kinetics,
signaling candidates), and (2) JNK signaling might be only one
of several possible downstream mediators of this complex.
Based on our findings, we cannot exclude that phosphatidylino-
sitol 3-kinase-related kinases contribute to the DNA damage
signaling pathway discovered in this study. Further studies are
needed to identify all important downstream signaling mediators
of caspase-8-dependent DDR.
Showing that the caspase-8-containing complex triggers
H2AX phosphorylation suggests that it controls DNA integrity
and thus potentially prevents malignant transformation. If this
holds true, loss of caspase-8 can be expected to be genotoxic
and generate an environment of genetic instability. In line with
these findings, caspase-8 deficiency has been shown to facili-
tate cellular transformation independently of its killing function
(Krelin et al., 2008). Loss of caspase-8 expression by either mu-
tations or epigenetic silencing has been reported in murine and
human HCC (Liedtke et al., 2005; Soung et al., 2005). Therefore,
it is conceivable that loss of caspase-8 in one and the same cell
not only confers apoptosis resistance (a hallmark of cancer), but
also promotes replication errors, and thus contributes to cancer
development. Based on our observations, caspase-8 deficiency
is thus expected to predispose to mutations in proliferating non-
neoplastic hepatocytes, whereas at the same time it should
confer a fitness disadvantage to neoplastic hepatocytes. In line
with the latter, data mining using distinct, already published
HCC cohorts revealed that low caspase-8 expression in HCC
is associated with a less aggressive behavior, reflected by a
less proliferative phenotype and a better overall survival. This
is reminiscent to the biology of mismatch repair (MMR) defi-
ciency in the colorectum. MMR deficiency on the one hand pre-
disposes to replication errors and cancer development, and on
the other hand it results in hyper-mutated tumors with a better
prognosis compared with MMR-proficient carcinomas (Gryfe
et al., 2000).
Given the here described role of caspase-8 in DDR, it is at first
glance counter-intuitive that deletion of caspase-8 rescued HCC
development in TAK1Dhep mice (Vucur et al., 2013). However,
DNA damage in a hyper-apoptotic environment such as in CLD
patients, Mcl-1Dhep, or TAK1Dhepmice, is provoked by constantly
enhanced regeneration causing replication stress. Taking into
account that caspase-8 deficiency in TAK1Dhep mice abolished
apoptosis and nearly normalized proliferative levels (Figure 4C;
Vucur et al., 2013), it is obvious that TAK1/Casp8Dhep mice are
not tumor prone.
In summary, we identified a role of caspase-8 in sensing DNA
damage, and have mechanistically linked increased hepatocyte
apoptosis with subsequent HCC development.
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Fwd TGCACCCTGACCCAGAATAC
Rev GCCAGGAGAATCGCAGTAGAA
This paper N/A
Murine FasL
Fwd GCAAATAGCCAACCCCAGTACAC
Rev GCCACCTTTCTTATACTTCACTCCAG
This paper N/A
Murine Tnfr1
Fwd CACCGTGACAATCCCCTGTAA
Rev TTTGCAAGCGGAGGAGGTAG
This paper N/A
Murine Tnfr2
Fwd ACAAAGTACCAAGGGTGGCA
Rev GGGCTTCTTTTTCCTCTGCAC
This paper N/A
Murine IL-6
Fwd TAGTCCTTCCTACCCCAATTTCC
Rev TTGGTCCTTAGCCACTCCTTC
This paper N/A
Murine IL-1a
Fwd CGA AGC TCT CCG TAC ATT CC
Rev TAA GGA CGG GAG GGA GAA AG
This paper N/A
Murine IL-1b
Fwd TAA GGA CGG GAG GGA GAA AG
Rev GAT CCA CAC TCT CCA GCT GCA
This paper N/A
Murine IL-18
Fwd GAC TCT TGC GTC AAC TTC AAG G
Rev CAG GCT GTC TTT TGT CAA CGA
This paper N/A
Murine Ifn-g
Fwd GCA TCC AAA AGA GTG TGG AG
Rev GCA GGC AGG ACA ACC ATT AC
This paper N/A
Murine Gadd45a
Fwd AGC ACG CAA AAG GTC ACA TTG
Rev GGG AAA GCA CTG CAC GAA CT
This paper N/A
Murine Actin
Fwd GTGGGCCGCCCTAGGCACCA
Rev CTCTTTGATGTCACGCACGATTTC
This paper N/A
Murine GAPDH
Fwd CCACCCCAGCAAGGAGACT
Rev GAAATTGTGAGGGAGATGCT
This paper N/A
Murine Rad51
Fwd CGGGAGTTGGTGGGTTATCC
Rev CCGGCACATCTTGGTTTATTTGT
This paper N/A
Murine Exo1
Fwd ATGGGGATTCAAGGGTTACTTCA
Rev AGCCAACAGTAGGTATCCACAG
This paper N/A
Murine Ddit3
Fwd CTCGCTCTCCAGATTCCAGTC
Rev CTTCATGCGTTGCTTCCCA
This paper N/A
Murine PolE2
Fwd TCCTCGAACATGATCGAACGA
Rev ACGTGGAATATCAAAAGCTCCAA
This paper N/A
Murine PolQ
Fwd GCTTGGTCACGTCTTGGAAG
Rev GGGCAAAATAAACAACGCTTTCT
This paper N/A
Murine Ddb1
Fwd ATGTCGTACAACTACGTCGTAAC
Rev CTGAAGTAAAGTGTCCGGTCAC
This paper N/A
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Murine Chek2
Fwd CTGAAGTAAAGTGTCCGGTCAC
Rev CACCACCCGGTCAAATAGTTC
This paper N/A
Murine Lig1
Fwd CCAGCTCATAGTCCCCTCTGA
Rev GTCTTGGCACCTCTAGCAGG
This paper N/A
Human Actin
Fwd ATGGCCCTGTGCCTTAGTAG
Rev GGTCTCAAACATGATCTGGG
This paper N/A
Human GAPDH
Fwd CCT GGT CAC CAG GGC TGC
Rev CCG TTC TCA GCC TTG ACG G
This paper N/A
Human Rad51
Fwd TTTGGTGAGTTTCCCGCTGTC
Rev AACTTCTTTGCTAAGCTCGGAG
This paper N/A
Human Exo1
Fwd CCTCGTGGCTCCCTATGAAG
Rev AGGAGATCCGAGTCCTCTGTAA
This paper N/A
Human Ddit3
Fwd GGAAACAGAGTGGTCATTCCC
Rev CTGCTTGAGCCGTTCATTCTC
This paper N/A
Human PolE2
Fwd TGAGAAGCAACCCTTGTCATC
Rev TCATCAACAGACTGACTGCATTC
This paper N/A
Human PolQ
Fwd ACCTCTCCATCAAGGCATTTCT
Rev GCAAAAGTTCCAGCAGATACC
This paper N/A
Human Ddb1
Fwd ACCGGACACTTTACTTCGGC
Rev TCGGCGGTGACCACATAGA
This paper N/A
Human Chek2
Fwd TGAGAACCTTATGTGGAACCCC
Rev ACAGCACGGTTATACCCAGC
This paper N/A
Human Lig1
Fwd ACAGTTCCCCATCAGGGATTC
Rev CTCTGTGAGGCTTTCTTTCGG
This paper N/A
Human Gpnmb
Fwd AAGTGAAAGATGTGTACGTGGTAACAG
Rev TCGGATGAATTTCGATCGTTCT
This paper N/A
Human Tinag
Fwd CGAAAGCTTCAGACACATGC
Rev TTTCTTTCTGCCCTTGTGCT
This paper N/A
Human Plk1
Fwd GCTTAATGACGAGTTCTTTACTTC
Rev TCGAAAACCTTGGTGGAATG
This paper N/A
Human Bcl2a1b
Fwd ACGACAGCAAATTGCCCCGGAT
Rev AAGCCATTTTCCCAGCCTCCGT
This paper N/A
Human Tpx2
Fwd CGAAAGCATCCTTCATCTCC
Rev TCCTTGGGACAGGTTGAAAG
This paper N/A
Human CD44
Fwd CCGCTATGTCCAGAAAGGA
Rev CTGTCTGTGCTGTCGGTGAT
This paper N/A
(Continued on next page)
e5 Cancer Cell 32, 342–359.e1–e10, September 11, 2017
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Achim
Weber (achim.weber@usz.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Material
Snap-frozen and formalin-fixed, paraffin-embedded (FFPE) human liver tissue samples were retrieved from the archives and the bio-
bank of the Department of Pathology andMolecular Pathology, University Hospital Zurich, formorphological andmolecular analyses.
The study was and approved by the local ethics committee (‘‘Kantonale Ethikkommission Z€urich’’, application numbers StV26/2005
and KEK-ZH-Nr. 2013-0382).
Mice
All animal experiments conformed to the relvant regulatory standards and were approved by the Swiss Veterinary Office (134/2014,
217/2012, 63/2011 Zurich). Animals were maintained under pathogen-free conditions and experiments were performed in
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Human Glypican3
Fwd CCTTTGAAATTGTTGTTCGCCA
Rev CCTGGGTTCATTAGCTGGGTA
This paper N/A
Human Epcam
Fwd AATCGTCAATGCCAGTGTAC
Rev TCTCATCGCAGTCAGGATCATAA
This paper N/A
Human Afp
Fwd AACTATTGGCCTGTGGCGAG
Rev TCATCCACCACCAAGCTG
This paper N/A
D3S1263-Fwd (FAM labeled)
CTG TTG ACC CAT TGA TAC CC
Thermo Fisher N/A
D3S1263-Rev (HEX labeled)
TAA AAT CAC AGC AGG GGT TC
Thermo Fisher N/A
D3S1289-Fwd (HEX labeled)
AAA GCA ACT TGT AAG AGA GCA
Thermo Fisher N/A
D3S1289-Rev (FAM labeled)
CTC CTA GAT ATA ATC ACT GGC A
Thermo Fisher N/A
Software and Algorithms
Copy Caller Software Life Technologies https://www.thermofisher.com
FlowJo sofware TreeStar https://www.flowjo.com
Summit software v4.3 Beckman Coulter https://www.beckman.com
GeneMapper software Applied Biosystems https://www.thermofisher.com
NDP Viewer v1.2.36 NDP View https://www.hamamatsu.com
Tissue IA image 2.0 Leica Biosystems www.leicabiosystems.com
GeneSpring GX Agilent http://www.genomics.agilent.com
GESA Molecular Signatures Database http://www.broadinstitute.org
Xcalibur software 2.2 Thermo Fisher Scientific https://www.thermofisher.com
R statistical programming language 3.2.2 R Foundation for Statistical Computing https://www.R-project.org/
cgdsr R package (R-Based API for Accessing the
MSKCC Cancer Genomics Data Server (CGDS))
CRAN repository https://CRAN.R-project.org/
package=cgdsr
SCAN.UPC R package Bioconductor project https://bioconductor.org/packages/
SCAN.UPC
Other
ABI 3130XL Genetic Analyzer Applied Biosystems https://www.thermofisher.com
Stella 3200 imaging system Raytest https://www.raytest.com/
Nano Zoomer C9600 Virtual Slide Light microscope
scanner
Hamamatsu https://www.hamamatsu.com
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accordance to the guidelines of the Swiss Animal Protection Law, Veterinary Office, Canton Zurich. Generation of mice with hepa-
tocyte-specific Mcl-1 knock-out (homozygous: AlbCretg/+/Mcl-1flox/flox (Mcl-1Dhep), heterozygous AlbCretg/+/Mcl-1flox/wt) (Vick et al.,
2009), with hepatocyte-specific c-Flip knockout and Tak1Dhep, Casp8Dhep, Tak1/Casp8Dhep and Tak1Dhep/RIPK3-/- mice (Vucur et al.,
2013), Xiap/ mice (Olayioye et al., 2005), and caspase 8 D387-mutant mice (Kang et al., 2008), was as described (see also Table
S1). TNFR1-/- and TNFR1/2-/- mice were purchased from Jackson Laboratories and TNFR1-/- mice intercrossed to Mcl-1Dhep mice
and bred in JNK1/2Dhep mice were generated by crossing with JNK1/2loxP/loxP mice (Das et al., 2011). Alb-Cre mice were bred
in house (Haybaeck et al., 2009). Ripk1-/-/Ripk3//Casp8/, Ripk3//Casp8/ and Ripk3/ mice were previously described
(Dillon et al., 2014).
Cell Lines and Drug Treatments
U2OS and HepG2 were grown in DMEM containing 10% FBS and 1% penicillin/streptomycin. Cells were transfected with lentiviral
particles for caspase-8 (Santa Cruz, sc-29930-V) or control particles (Santa Cruz, sc-108080) according to the manufacturer’s pro-
tocol and cells stably expressing the shRNA were isolated by puromycin selection (Santa Cruz). Cells were treated as indicated with
Doxorubicin (Sigma) and for inhibition experiments, cells were pretreated for 4h with 10mM of the ATM inhibitor KU-55933
(Selleckchem) or pretreated with the JNK inhibitor (SP600125, Selleckchem) at 25mM and Doxorubicin added and cells incubated
for indicated time. Cells 2h post irradiation with 10Gy were used as controls.
METHOD DETAILS
Human Cohort Studies
For evaluation of liver function tests as potential predictors of HCC development, HCV patients with confirmed diagnosis of HCC and
HCV patients without HCC were selected from the patient database as matched pairs according to MELD score for the given time
point before the HCC diagnosis. TheMELD score was chosen as the current international standard for assessment of severity of liver
disease e.g. in liver transplant organ allocation and is based on laboratory values bilirubin, creatinine and INR. HCV patients who un-
derwent liver transplantation (Swiss Hepato-Pancreato-Biliary Center, University-Hospital Zurich) due to liver tumorswere chosen for
the transplantation study, and compared to HCV patients which underwent liver transplantation, but did not develop liver tumors.
Mouse Strains and Intercrossings
Live damage of mice at the indicated age and tumor incidence analyzed at 12 months of age for Mcl-1Dhep and Mcl-1Dhep/TNFR1-/-
mice and 33-35 weeks of age for TAK1Dhep mice and intercrossings. For overview, please also see Table S1.
Measurement of Serum Parameters
The analysis of aminotransferases (ALT/AST) and bilirubin was performed with mouse serum on a Roche Modular System (Roche
Diagnostics) with a commercially available automated colorimetric system at the Institute of Clinical Chemistry, University Hospital
Zurich, using a Hitachi P-Modul (Roche).
RNA Isolation from Liver Tissue
Total RNA from snap-frozen human liver biopsies or mouse livers was isolated using RNeasy Mini Kit (Qiagen) according to the man-
ufacturer’s protocol. The quantity and quality of the RNA was determined spectroscopically using a Nanodrop (Thermo Scientific).
Real-time PCR
Total RNA (1 mg) was reversely transcribed into cDNA using Quantitect Reverse Transcription Kit (Qiagen) according to the manufac-
turer’s protocol. FormRNA expression analysis real-time PCR was performed (reactions in duplicates) using Fast Start SYBR Green
Master Rox (Roche). Real-time PCR was performed on an ABI PRISM 7900 HT and VIIA7 Fast Real-Time PCR System (AB). Data
were generated and analyzed using SDS 2.4 and RQmanager 1.2 software.mRNA expression levels were normalized to the house-
keeping genes Hprt for human samples, and Gapdh for murine samples.
DNA Extraction
Genomic DNA was isolated from 2 mm sections of murine or human FFPE slides by scrapings and tissue digested with Proteinase K
overnight. After Proteinase K inactivation for 10min at 95CDNA concentration was determined spectroscopically using a Nanodrop
(Thermo Scientific) and appropriate genomic DNA was directly used for PCR reactions in duplicates.
Taqman Copy Number Analysis
Taqman copy number analysis was carried out as multiplex PCR in duplicates with 20 ng DNA per reaction and Ttert as internal refer-
ence according to the manufacturer’s protocol.Wwox, Spata22, Fhitwere selected as described markers from common fragile sites
in humans and Fgfr1 and Fgrwere selected as genes of interest in previously published areas of genetic instability in Tak1Dhep-/- mice
(Bettermann et al., 2010). Data analysis was performed using Copy Caller Software (Life Technologies).
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Flow Cytometry for DNA Damage
Primary murine hepatocytes were isolated by the two-step collagenase perfusion method, purified by Percoll gradient and finally
collected in RPMI 1640 medium for flow cytometry procedures. Next, hepatcytes were fixed and permeabilized, followed by
incubation with antibodies against gH2AX (#9718; Cell Signaling Technology) and RPA (NA19L, Calbiochem) and suitable secondary
antibodies. DNA was stained with 1 mg/ml DAPI. Samples were measured on a Cyan ADP flow cytometer (Beckman Coulter) and
analyzed with Summit software v4.3 (Beckman Coulter).
Partial Hepatectomy (PHX)
Eight- to twelve-week-old male mice with indicated genotype received food and water ad libitum before surgery. Mice were anaes-
thetized by inhalation of isoflurane (2%). PHX was performed between 8 and 12 a.m..Three liver lobes, including the previously
emptied gall bladder, were removed. After surgery, mice were injected with buprenorphine for analgesia (Temgesic; Essex Chemie
AG, Luzern, Switzerland; 0.1 mg/kg of body weight). Mice were euthanized by CO2 inhalation, and the remaining liver was harvested
at different time points after PHX for further analysis (Speicher et al., 2014).
BrdU Assay
Proliferating cells were identified by 5-bromo-20-deoxyuridine (BrdU) labelling. For this purpose, BrdU (Sigma, Buchs, Switzerland;
250 mg/g body weight) was injected i.p. prior to PHX. Two hours later, PHXwas performed andmice were sacrificed at indicated time
points. Detection of BrdU-positive cells was performed by immunofluorescence stainings using a peroxidase-coupled antibody
against BrdU (1:30; Roche, Switzerland) (Speicher et al., 2014).
Immunoprecipitation
Cells were lysed in 1 ml lysis buffer (20 mM Tris HCl, pH 7.4, 137 mM NaCl, 2 mM EDTA, 10% glycerine, 1% Triton X-100, 1 mM
PMSF, Protease Inhibitor mix (Roche)) for 30 min on ice. Afterwards, the samples were centrifuged at 14.000 rpm for 15 min at
4C. 50 ml supernatant was used as lysate control. The remaining supernatant was immunoprecipitated by mixing with 30 ml protein
A-Sepharose and 2 mg of C15 antibodies. Immunoprecipitations were performed for at least 2h at 4 C and washed four times
with PBS. Samples were subjected to SDS PAGE (Biorad) and transferred to Hybond nitrocellulose membrane using the Western
Blot system (Biorad). Membranes were blocked with 5% nonfat dry milk in PBS-T (PBS + 0.05% Tween 20) for 1 h, washed with
PBS-T 3x for 10 min and incubated with the primary antibody in PBS/Tween for 1h at room temperature. C15 (anti-caspase 8)
and 1C4 (anti-FADD) antibodies were a kind gift of Prof. Peter H. Krammer (DKFZ, Heidelberg). The following antibodies were
used: anti-RIPK1 (D94C12), Cell Signaling, anti-Casp3 (9662), Cell Signaling and anti-Actin (A2103), Sigma.
Fragment Length Analysis for Allelic Imbalance
For analysis of AI the markers D3S1263 and D3S1289 at known common fragile sites (Gorgoulis et al., 2005) were selected. Four
distinct regions (non-inflamed) of interest per liver-needle biopsy were identified by pathologists and gDNA isolated from 2 mm
unstained consecutive FFPE sections. PCR products were separated by capillary electrophoresis using the ABI 3130XL Genetic
Analyzer (Applied Biosystems) and results were analyzed with the help of GeneMapper software (Applied Biosystems). AI was iden-
tified by calculating the fluorescence ratios of heterozygous (informative) markers for each biopsy. The following primers were used:
D3S1263-FwdCTG TTGACCCAT TGA TACCC (FAM labeled),D3S1263-Rev TAA AATCACAGCAGGGGT TC,D3S1289-Fwd AAA
GCA ACT TGT AAG AGA GCA (HEX labeled), D3S1289-Rev CTC CTA GAT ATA ATC ACT GGC A.
Pulse Field Gel Electrophoresis (PFGE)
PFGE was performed as published previously (Neelsen et al., 2013). Briefly, snap-frozen liver tissue was directly put into 4% form-
aldehyde without thawing and incubated for 10min at 37C. Tissue wasmechanically dissociated (gentleMACS Dissociator, Miltenyi
Biotec), filtered through a 70 mmcell strainer (Falcon) and 2.5x105 cell were embedded in a 0.8% agarose plus, digested in lysis buffer
(100mMEDTA, 1% (wt/vol) sodium lauryl sarcosyne, 0.2% (wt/vol) sodium deoxycholate, and 1mg/ml proteinase K) at 37C for 48 h,
and washed in 10 mM Tris-HCl, pH 8.0, and 100 mM EDTA. Electrophoresis was performed at 14C in 0.9% (wt/vol) Pulsed Field
Certified Agarose (Bio-Rad Laboratories) containing Tris-borate/EDTA buffer in a CHEF DR III apparatus (9 h, 120, 5.5 V/cm,
30-18 s switch time; 6 h, 117, 4.5 V/cm, 18-9 s switch time; 6 h, 112, 4 V/cm, 9-5 s switch time; Bio-Rad Laboratories). The gel
was stained with ethidium bromide and imaged on an Alpha Innotech Imager.
Immunoblot Analysis
Snap-frozen liver tissue was dissociated (gentle MACS Dissociator, Miltenyi Biotec) and homogenates (10%) were prepared in RIPA
buffer (50 mM Tris; 1% NP40; 0.25% Deoxycholic acid sodium salt; 150 mM NaCl; 1 mM EGTA) containing Halt Protease and
Phosphatase Inhibitor Cocktail (Thermo Scientific). Quantification with a BCA protein assay kit (Thermo Scientific) according to the
manufacturer’s manual was followed by denaturation of 80 mg protein in Laemmli buffer containing 5% b-mercaptoethanol and
separated by gel electrophoresis (Mini Protean Gels, Bio Rad) and blotted by semi-dry blotting (Trans-Blot Turbo Transfer, Bio Rad)
onto nitrocellulose membranes (Bio Rad) and stained with Ponceau Red. Membranes were blocked in 5% milk/PBS-T for at least
1 hr at RT. Primary antibodies against gH2AX, p-p53, GAPDH, PCNA, pATM, pCHK1, pJNK1/2, pCHK2, pATR, pBRCA1, cleaved-
Casp1, cleaved-Casp3, cleaved-Casp8, RIPK1, RIPK3, total-JNK1/2, p-p38, p38, cIAP1, cIAP2, XIAP (all Cell Signaling Technology),
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total-Casp8, p-cJUN, pAKT1/2/3, total AKT (SantaCruz), total-ATM (Sigma), total-cJUN (BD Bioscience), HOIP (R&D), SHARPIN (Pro-
teintech), HOIL-1 (Walczak lab) and Casp8 C15 (provided by Dr. P. Krammer, Heidelberg), were incubated at 4C overnight under
shaking conditions. Incubationwith the secondary antibody (HRP-anti rabbit IgG, 1:5000; Promega) was performed under shaking con-
ditions for 1 hr. Detection was achieved with Clarity Western ECL Substrate (Bio Rad) using Stella 3200 imaging system Raytest.
Histology and Immuno Stainings
Sections (2 mm) of livers (fixed in 4% paraformaldehyde and paraffin-embedded) were stained with Hematoxylin/Eosin or various an-
tibodies. Incubation in Ventana buffer and staining was performed on a NEXES immunohistochemistry robot (Ventana Instruments)
using an IVIEW DAB Detection Kit (Ventana) or on a Bond MAX (Leica). Immunostainings were performed as described before (Wolf
et al., 2014) with antibodies against the following proteins: Ki67, 1:200 dilution (SP6, NeoMarkers / Lab Vision Corporation); gH2AX,
1:300 dilution (Novus Biologicals); p-cJUN, 1:100 (Abcam); cleaved-Caspase8, 1:500; p-CHK1, 1:50 and p-CHK2, 1:500 (Novus
Biologicals). For virtual microscopy and archiving, histological and immunohistochemical images were digitalized using a Nano
Zoomer C9600 Virtual Slide Light microscope scanner by Hamamatsu using NDP, View Software, version 1.2.36. Alternatively, for
quantification of stainings, slides were scanned using a SCN 400 slide scanner (Leica) and analyzed using Tissue IA image analysis
software (Slidepath, Leica).
RNA Microarray
An Agilent one-color microarray-based gene expression analysis (mouse DNA Microarray 4x44K) was performed according to the
manufacturer’s protocol. Two- and twelve-months-old mice were analyzed. For 12 months, HCC and corresponding non-tumor tis-
sue (n=3) from the same animal (n=5) as well as livers from Cre-negative littermates as controls (n=3) were analyzed. For 2 months,
Mcl-1Dhep (AlbCretg/+Mcl-1flox/flox), hemizygous Mcl-1Dhep (AlbCretg/+/Mcl-1flox/wt) and Cre-negative controls were analyzed. Gene
expression was quantified using Agilent Feature Extraction Software Version 9.5.3.1. Gene Ontology microarray data analysis: Lists
of significantly differentially expressed genes were investigated in respect to enrichment of GeneOntology categories using theGene
Ontology Browser as implemented in GeneSpring 7.3. Fisher’s exact test was used to showwhethermore genes belonging to aGene
Ontology category are found in the list under investigation than in a randomized gene list of the same size.
Gene Set Enrichment Analysis (GSEA)
Gene sets from the biological process gene ontology for GSEA analysis http://www.broadinstitute.org were downloaded from the
Molecular Signatures Database or integrated manually into the GSEA for human HCV-induced hepatitis gene expression sets (Sar-
asin-Filipowicz et al., 2008) or alcohol-induced hepatitis (Affo et al., 2013). GSEA tests whether genes sets were overrepresented in
microarray expression data were performed with standard settings.
Immunofluorescence Stainings and Confocal Microscopy
U2OS cells were seeded on cover slips and grown to 50-80% confluence for 24 h. Cells were incubated with medium or 1 mM doxo-
rubicin for 30 min and fixed with 4% fomaldehyde for 1 h. Cells were washed with PBS and Tris buffer (100 mM Tris, pH=7.4, 50 mM
NaCl), permeabilized with 0.5% Triton X-100 in PBS for 10 min, incubated in blocking solution (PBS, pH=7.4, 1% BSA, 2% FCS) for
20 min, incubated with primary antibody in blocking solution for 12 h at 4C, washed twice with PBS, incubated with secondary anti-
body in blocking solution for 3 h, washed with PBS, incubated with 1 mg/ml DAPI (life technologies) for 5-15 min, washed 4 times with
PBS and mounted using Vectashield (Vector Laboratories). Primary antibodies and concentrations used for immunofluorescence
were gH2AX (Abcam, ab26350, 1:200), gH2AX (Novus Biologicals, NB100-2280, 1:200), RIP1 (BD Biosciences, 610459, 1:50), Cas-
pase 8-C15 and 53BP1 (Santa-Cruz, sc-22760, 1:50). Secondary, Alexa-488 or Alexa-546 labelled antibodies were all from life tech-
nologies and used at a 1:500 dilution. Imaging was performed on a Leica SP8 confocal microscope equipped with 405, 488, 552, and
638 nm diode lasers and a 63x oil objective (HC PL APO CS2 / 1.40 oil) using LAS software (Leica Microsystems, Wetzlar Germany)
and processed using ImageJ.
Subcellular Fractionation
Cells grown on dishes were washed twice with ice-cold PBS and carefully scraped in PBS, centrifuged at 1000 x g for 2 min at 4C
and resuspended in 300 ml buffer A (20 mM Tris/HCl pH 7.9, 10 mM NaCl, 1.5 mM MgCl2, 10 % Glycerol, 0.5 mM DTT, 0.5 mM
AEBSF, 1 mM Na3VO4, 1 mM Na2MoO4, 10 mM NaF, 10 mM K2HPO4, 20 mM glycerol-2-phosphate, phosphatase inhibitor tablet
(Roche)). After incubation on ice for 10 min, swelling of cells was monitored by microscopy using 0.4% trypan blue staining. For
disruption of the cytoplasm membrane cells were treated with 0.125% NP-40 and incubated on ice for 5 min. After centrifugation
at 2000 x g for 10 min at 4C the supernatant was kept as cytosolic fraction (additional centrifugation at 13000 x g for 10 min at
4C freed the lysate from cell debris). Nuclear fractions were resuspended in 100 ml buffer C (20 mM Tris/HCl pH 7.9, 420 mM
NaCl, 1.5 mM MgCl2, 10% gycerol, 0.5 mM DTT, 0.2 mM EDTA, 0.5 mM AEBSF, 1 mM Na3VO4, 1 mM Na2MoO4, 10 mM NaF,
10 mM K2HPO4, 20 mM glycerol-2-phosphate, phosphatase inhibitor tablet (Roche)). After incubation for 15 min on ice with occa-
sional vortexing N1 fractions were collected by centrifugation at 13000 x g for 10 min at 4C. Pellets were resuspended in 50 ml buffer
E (20mMTris/HCl pH 7.9, 150mMNaCl, 1.5mMMgCl2, 10%glycerol, 0.5mMAEBSF, 1mMNa3VO4, 1mMNa2MoO4, 10mMNaF,
20 mM glycerol-2-phosphate, phosphatase inhibitor tablet (Roche), 1 ml Benzonase Nuclease (25 U/ml, Novagen) and 2%SDS). After
incubation for 30 min at 4C with shaking N2 fractions were collected by centrifugation at 13000 x g for 10 min at 4C.
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AQUA-Mass Spectrometry
Immunoprecipitates (sepharose beads) were suspended in 50 mM NH4HCO3 and cysteins were ß-thiomethylated by dithiothreitol
reduction (1 mM DTT, 56C, 45 min) and subsequent S-Methyl methanethiosulphonate (MMTS) treatment (5 mM MMTS, 30 min).
Tryptic digestion was performed by addition of 0.5 mg Trypsin (Trypsin Gold, Promega) and incubated at 37C for 24 h. AQUA pep-
tides for caspase 8, FADD, c-Flip and RIPK1 were spiked into the digestion solution in an absolute amount of 50 fmol of each peptide
as described previously (Schleich et al., 2015). Sequences of AQUA peptides could be received upon request. After digestion, the
supernatant was collected and dried down in a vacuum centrifuge. The peptides were redissolved in 5 ml 0.1 % trifluoroacetic
acid (TFA) and purified on ZIP-TIP, C18-nanocolumns (Millipore, Billerica, USA). Peptides were eluted in 7 ml 70% (v/v) acetonitrile
(ACN) and subsequently dried in a vacuum centrifuge. Dried samples were dissolved in 10 ml 2% ACN/0.1% TFA and separated
on a 75 mm I.D., 25 cm PepMap C18-column (Dionex, Sunnyvale, USA) applying a gradient from 2% to 45% ACN in 0.1% formic
acid over 120 min at 300 nl/min using an Ultimate 3000 Nano-HPLC (Thermo Scientific, San Jose, USA). Mass spectrometry was
performed on a hybrid dual-pressure linear ion trap/orbitrap mass spectrometer (LTQ Orbitrap Velos Pro, Thermo Scientific, San
Jose, USA) in exclusive orbitrap full MS mode (FTMS; resolution 60,000; m/z range 400-2000). Instrument control, data acquisition
and peak integration were performed using the Xcalibur software 2.2 (Thermo Fisher Scientific). Extracted ion chromatograms
derived from Orbitrap mass scans from each AQUA/target peptide pair were generated and the peak areas of the light and heavy
peptide were obtained by manual integration, respectively. The heavy to light ratio of each AQUA peptide pair was calculated and
the resulting absolute amount of the endogenous (light) peptide was determined.
Analysis of Data from Human Hepatocellular Carcinoma
Data mining was performed to assess the relevance of caspase 8 in HCC. All analyses were performed using the R statistical pro-
gramming environment, version 3.2.2. Publicly available data from the Cancer Genome Atlas (TCGA) project were used. Clinical data
and Level 3 RNA sequencing data were downloaded from the TCGA website (https://tcga-data.nci.nih.gov/ – files nationwidechil-
drens.org_LIHC.bio.Level_2.0.54.0 and unc.edu_LIHC.IlluminaHiSeq_RNASeqV2.Level_3.1.14.0, respectively). Methylation data
were downloaded via cBioPortal (http://www.cbioportal.org/) using the cgdsr R package on 11th November 2015. Patients with fi-
brolamellar hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma were excluded. The UPC (Universal
exPression Codes) method, as implemented by the SCAN.UPC R/Bioconductor package (Piccolo et al., 2013), was used to evaluate
whether genes within the TCGA dataset should be considered to be expressed in individual patients (UPC values > 0.5 indicating
expression of the gene). Count data from RNA sequencing were transformed using the formula log2 (x + 1) to better approximate
a normal distribution. Methylation data from cBioPortal were dichotomized using a percentage of methylation (b) cutoff of 0.3
(< 0.3 unmethylated, > 0.3 methylated). The log rank test was used to assess association with survival. For RNA expression, the me-
dian, the mean + 1 standard deviation (shown in the final figure), and the mean - 1 standard deviation were initially used as cutoffs to
separate patients into two groups according to the level of CASP8 expression; the p value shown in the final figure was corrected for
3 tests using the Bonferroni method. Spearman’s rank correlation coefficient was used to assess the correlation between genes.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis
Statistical analysis was performed using GraphPad Prism software (version 5.0) or SPSS. All data are presented as mean ± SEM
and were analyzed by ANOVA with Bonferroni correction. Analysis of two samples was performed with Student t test, statistics
for HCC incidence were calculated using Fisher’s Exact test. Statistical significance is indicated as follows: ****p < 0.0001;
***p < 0.001; **p < 0.01; *p < 0.05; n.s. not significant.
Modelling of Mutation Rates Depending on Proliferative Activity
A rough calculation of the replication error rates depending on the replication rate inwild typemice andMcl-1Dhepmicewith low trans-
aminase levels and corresponding low proliferative activity or Mcl-1Dhep mice with high transaminase levels and corresponding high
proliferative activity. Modelling was based on proliferation rates determined by Ki67+ hepatocytes at 2 months of age revealing that
Mcl-1Dhep mice have about 10- to 25-fold higher Ki67 rates (see Figure 2). Calculation is based on the following assumptions: A wild
typemouse liver weighting 2 g consists of2x108 hepatocytes, and assuming a proliferation index of 0.2 (Eldridge and Goldsworthy,
1996), 4x105 proliferating hepatocytes. Further, assuming an replication error rate of 10-8 per cell per generation (Tago et al., 2005),
and 24 h cycle duration (Alexiades and Cepko, 1996), taking Poisson distribution as basis, the expected number of replications errors
after 1 year of is 1.46 for wild typemice, 14.6 for Mcl-1Dhep mice with low hepatocyte proliferative activity, and 36.8 for Mcl-1Dhep mice
with high hepatocyte proliferative activity.
DATA AND SOFTWARE AVAILABILITY
Gene expression microarray data are deposited in the GEO database under accession number GSE75730.
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